Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) vs. Basal-Bolus (BB) Therapy in Patients with Type 2 Diabetes (T2D): DUAL VII Trial

被引：0
|
作者：
Billings, Liana K.
Doshi, Ankur
Gouet, Didier
Oviedo, Alejandra
Rodbard, Helena W.
Tentolouris, Nikolaos
Gron, Randi
Halladin, Natalie
Jodar, Esteban
机构：
来源：
DIABETES | 2017年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
136-OR
引用
收藏
页码：A36 / A36
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of insulin degludec/liraglutide (IDegLira) vs basal-bolus therapy in patients with type 2 diabetes: DUAL VII trial
    Billings, L. K.
    Doshi, A.
    Gouet, D.
    Oviedo, A.
    Rodbard, H. W.
    Tentolouris, N.
    Gron, R.
    Halladin, N.
    Jodar, E.
    DIABETOLOGIA, 2017, 60 : S366 - S366
  • [2] Patient-Reported Outcomes (PROs) in Insulin Degludec/Liraglutide (IDegLira) vs. Basal-Bolus (BB) Therapy in Patients (Pts) with Type 2 Diabetes (T2D): DUAL VII Trial
    Billings, Liana K.
    Doshi, Ankur
    Gouet, Didier
    Oviedo, Alejandra
    Rodbard, Helena W.
    Tentolouris, Nikolaos
    Kirstine Busk, Anne
    Basse, Amaury
    Jodar, Esteban
    DIABETES, 2017, 66 : LB32 - LB32
  • [3] Patient-reported outcomes with insulin degludec/liraglutide (IDegLira) vs basal-bolus therapy in patients with type 2 diabetes: DUAL VII trial
    Jodar, E.
    Doshi, A.
    Gouet, D.
    Oviedo, A.
    Rodbard, H. W.
    Tentolouris, N.
    Busk, A. K.
    Basse, A.
    Billings, L. K.
    DIABETOLOGIA, 2017, 60 : S370 - S370
  • [4] Efficacy of IDegLira vs. Basal-Bolus Therapy in Subjects with Type 2 Diabetes in DUAL VII by Baseline Characteristics
    Billings, Liana K.
    Klonoff, David C.
    Tentolouris, Nikolaos
    Gron, Randi
    Halladin, Natalie
    Jodar, Esteban
    DIABETES, 2018, 67
  • [5] The Benefit of Insulin Degludec/Liraglutide (IDegLira) Compared With Basal-Bolus Insulin Therapy is Consistent Across Participant Subgroups With Type 2 Diabetes in the DUAL VII Randomized Trial
    Billings, Liana K.
    Agner, Bue F. Ross
    Altuntas, Yuksel
    Gron, Randi
    Halladin, Natalie
    Klonoff, David C.
    Tentolouris, Nikolaos
    Jodar, Esteban
    JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY, 2021, 15 (03): : 636 - 645
  • [6] Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial
    Billings, Liana K.
    Doshi, Ankur
    Gouet, Didier
    Oviedo, Alejandra
    Rodbard, Helena W.
    Tentolouris, Nikolaos
    Gron, Randi
    Halladin, Natalie
    Jodar, Esteban
    DIABETES CARE, 2018, 41 (05) : 1009 - 1016
  • [7] iGlarLixi vs. Basal-Bolus (BB) or Premixed Insulin in Older Adult Ethnic Minorities with Type 2 Diabetes (T2D)
    Umpierrez, Guillermo
    Gill, Jasvinder
    Hood, David
    Li, Xuan
    Nunez, Ana
    DIABETES, 2024, 73
  • [8] Evaluation of the Short-Term Cost-Effectiveness of Insulin Degludec/Liraglutide (IDegLira) vs. Basal-Bolus Therapy in the USA
    Billings, Liana K.
    Mocarski, Michelle
    Slothuus, Ulla
    Hunt, Barnaby
    Valentine, William
    Jodar, Esteban
    DIABETES, 2017, 66 : A254 - A255
  • [9] Initiation of iGlarLixi vs. Basal-Bolus Insulin (BB) in Adults with Type 2 Diabetes (T2D) Advancing from Basal Insulin (BI) Therapy: The SoliComplex Real-World Study
    Pantalone, Kevin M.
    Heller, Caroline
    Lajara, Rosemarie
    Lew, Elisheva
    Li, Xuan
    Dex, Terry A.
    Kilpatrick, Rachel
    DIABETES, 2022, 71
  • [10] Superior Effects with Combination of Insulin Degludec (IDeg) and Liraglutide (Lira) (IDeg plus Lira) Compared with Basal-Bolus Insulin Therapy (BB) in Hemodialysis (HD) Patients with Poorly Controlled Type 2 Diabetes (T2D): An Assessment by Continuous Glucose
    Funakoshi, Satoshi
    Hashiguchi, Jyunichiro
    Etoh, Rica
    Ikeda, Kouhei
    Harada, Takashi
    Utsunomiya, Kazunori
    Mori, Yutaka
    DIABETES, 2015, 64 : A45 - A45
12345